Radiolabelled 177 Lu‐Bispidine‐Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers
Chemistry – A European Journal · 2024
DOI: 10.1002/chem.202303805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Patrick A Cieslik und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland. Hauptthemen laut MEDLINE: Radioisotopes, Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid‐selective nonadentate bispidine ligand suitable for 177 Lu 3+ ion complexation. The ligand (bisp, 1 ) was derivatised with a photoactivatable aryl azide (ArN 3 ) group as a bioconjugation handle for light‐induced labelling of proteins. Quantitative radiosynthesis of [ 177 Lu]Lu‐ 1 + was accomplished in 10 minutes at 40 °C. Subsequent incubation of [ 177 Lu]Lu‐ 1 + with trastuzumab, followed by irradiation with light at 365 nm for 15 min, at room temperature and pH 8.0–8.3, gave the radiolabelled mAb, [ 177 Lu]Lu‐ 1 ‐azepin‐trastuzumab ([ 177 Lu]Lu‐ 1 ‐mAb) in a decay‐corrected radiochemical yield of 14 %, and radiochemical purity (RCP)>90 %. Stability studies and cellular binding assays in vitro using the SK‐OV‐3 human ovarian cancer cells confirmed that [ 177 Lu]Lu‐ 1 ‐mAb remained biological active and displayed specific binding to HER2/ neu . Experiments in immunocompromised female athymic nude mice bearing subcutaneous xenograft models of SK‐OV‐3 tumours revealed significantly higher tumour uptake in the normal group compared with the control block group (29.8±11.4 %ID g −1 vs. 14.8±6.1 %ID g −1 , respectively; P ‐value=0.037). The data indicate that bispidine‐based ligand systems are suitable starting points for constructing novel, high‐denticity chelators for specific complexation of larger radiotheranostic metal ion nuclides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
- Klinik für Kleintierchirurgie, Vetsuisse-Fakultät, University of Zurich, Wintherturerstrasse 260, CH-8057, Zurich, Switzerland.
ORCID-Profile: Patrick A Cieslik, Simon Klingler, Jason P Holland
Förderung
- Horizon 2020 Framework Programme
Zitieren
APA
Cieslik, P. A., Klingler, S., Nolff, M., & Holland, J. P. (2024). Radiolabelled 177 Lu‐Bispidine‐Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers. Chemistry – A European Journal. https://doi.org/10.1002/chem.202303805
Vancouver
Cieslik PA, Klingler S, Nolff M, Holland JP. Radiolabelled 177 Lu‐Bispidine‐Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers. Chemistry – A European Journal. 2024. doi:10.1002/chem.202303805
BibTeX
@article{Cieslik2024,
author = {Cieslik, Patrick A and Klingler, Simon and Nolff, Mirja and Holland, Jason P},
title = {Radiolabelled 177 Lu‐Bispidine‐Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers},
journal = {Chemistry – A European Journal},
year = {2024},
doi = {10.1002/chem.202303805}
}
EUVIMED